These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23696193)

  • 1. Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors.
    Vandoros S
    Health Econ; 2014 May; 23(5):621-30. PubMed ID: 23696193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands.
    Klok RM; Boersma C; Oosterhuis I; Visser ST; de Jong-van den Berg LT; Postma MJ
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1595-600. PubMed ID: 16696808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
    Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases.
    Gray AL; Santa-Ana-Tellez Y; J Wirtz V
    Trop Med Int Health; 2016 Dec; 21(12):1504-1512. PubMed ID: 27671539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
    Mahlich JC; Stadler I
    Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug substitution associated with a hospital stay in Belgium: a retrospective analysis of a claims database.
    Simoens S; Dubois C; Spinewine A; Foulon V; Paulus D
    Int J Pharm Pract; 2014 Apr; 22(2):105-11. PubMed ID: 23829345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyzing generic and branded substitution patterns in the Netherlands using prescription data.
    Pechlivanoglou P; van der Veen WJ; Bos JH; Postma MJ
    BMC Health Serv Res; 2011 Apr; 11():89. PubMed ID: 21524312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitors prescribing following the introduction of generic drugs.
    Cammarota S; Bruzzese D; Sarnelli G; Citarella A; Menditto E; Riegler S; Savino IG; Vozzella L; Piccinocchi G; Napoli L; Arpino G; Cuomo R
    Eur J Clin Invest; 2012 Oct; 42(10):1068-78. PubMed ID: 22681176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.
    Boersma C; Klok RM; Bos JM; Naunton M; van den Berg PB; de Jong-van den Berg LT; Postma MJ
    Appl Health Econ Health Policy; 2005; 4(3):191-6. PubMed ID: 16309337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The generic drug market in Japan: will it finally take off?
    Iizuka T; Kubo K
    Health Econ Policy Law; 2011 Jul; 6(3):369-89. PubMed ID: 21205400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.
    Fraeyman J; Van Hal G; De Loof H; Remmen R; De Meyer GR; Beutels P
    Acta Clin Belg; 2012; 67(3):160-71. PubMed ID: 22897063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers.
    Growdon ME; Sacks CA; Kesselheim AS; Avorn J
    JAMA Intern Med; 2019 Dec; 179(12):1712-1714. PubMed ID: 31380893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Generic and biosimilar drug substitution: a panacea?].
    Daly MJ; Guignard B; Nendaz M
    Rev Med Suisse; 2015 Oct; 11(490):1909-12, 1914. PubMed ID: 26665661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pfizer receives US$2.15 billion in patent damages.
    Sklan A
    Pharm Pat Anal; 2013 Sep; 2(5):583. PubMed ID: 24386655
    [No Abstract]   [Full Text] [Related]  

  • 19. Private expenditures on brand name prescription drugs after generic entry.
    Balaban DY; Dhalla IA; Law MR; Bell CM
    Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.